ClinicalTrials.gg
TerminatedNCT05429502Updated Oct 10, 2025

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

A Phase 1 interventional study of Topotecan and Temozolomide in Neuroblastoma, sponsored by Novartis Pharmaceuticals. Terminated at 6 sites in 4 countries. Open to participants aged 12 Months to 21 Years. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Why this study was terminated
Study halted early due to high toxicity risk (from BHLRM model) in combo treatment and inability to identify recommended Phase 2 dose in initial phase (Phase 1-Part A), making continuation to subsequent phases (Phase 1-Part B and Phase 2) unfeasible.

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
12 Months to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing topotecan in Neuroblastoma — 2 open to participants now, 4 under way, none of them phase 3. Topotecan · Neuroblastoma.

Enrollment
18th of 20
12 · median 30
Started
2022
with 1 other
Phase 1
7 of 20
none open now
Registered
19th of 20
by date

Among the 20 studies testing topotecan in Neuroblastoma, this one is the 18th largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 1, and was the 19th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 128 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

2 of the 20 studies testing topotecan in Neuroblastoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About topotecan

Topotecan: first FDA approval 1996 (HYCAMTIN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 105 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 75 (71%) stop at 75 or younger; 102 take children under 18; 3 take healthy volunteers.

This study: 12 Months to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing topotecan in Neuroblastoma, or all of them as a file.
02

Study summary

This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors, including medulloblastoma (MB), high-grade glioma (HGG), malignant rhabdoid tumors (MRT), and rhabdomyosarcoma (RMS).

Read the detailed description

The study is structured into two parts: Phase I - Part A (dose finding) and Phase I - Part B (multiple expansion cohorts). Phase II may commence following the evaluation of Phase I data, which includes safety, tolerability, efficacy, pharmacokinetics, and biomarker data. Additionally, other emerging data that could influence the treatment landscape will be considered before initiating Phase II in patients with relapsed or refractory neuroblastoma (NB) and/or other tumors studied in Phase I.

- Phase I - Part A (dose finding): This phase aims to determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D) of ribociclib in combination with TOTEM.

Due to the early termination of the trial, Phase I - Part B (multiple expansion cohorts) and Phase II (double-blind, randomized, placebo-controlled in relapsed or refractory NB) were not initiated.

03

Conditions studied

  • Neuroblastoma

Keywords

  • neuroblastoma
  • medulloblastoma
  • high-grade glioma
  • malignant rhabdoid tumors
  • rhabdomyosarcoma
  • relapsed
  • refractory
  • pediatric
04

Who can participate

Ages eligible
12 Months to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants and/or guardian have the ability to understand and the willingness to sign a written document.
  2. Age ≥ 12 months and ≤ 21 years at the time of signing consent form Note: The first dose level of Phase I - part A (dose finding) will enroll participants ≥ 12 years - 21 years old, and may expand to younger participants (≥ 12 months to \< 12 years) as determined by the data.
  3. or cytologically confirmed solid tumors listed below that have progressed despite standard therapy or for which no effective standard therapy exists.

    1. Neuroblastoma (for Phase I and Phase II): Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS); disease; per International Neuroblastoma Response criteria (INRC); Bone marrow only disease not eligible; Available MYCN status before screening
    2. Medulloblastoma (for Phase I) regardless of genetic status (i.e. Groups 3 or 4 WNT-activated or non-WNT, SHH-activated or non-SHH)
    3. High-grade glioma (for Phase I): including HGG NOS, WHO Grade III or Grade IV; Glioblastoma, IDH-wildtype or IDH-mutant; Anaplastic astrocytoma, IDH-mutant; Anaplastic oligodendroglioma, IDH-mutant; Anaplastic pleomorphic xanthoastrocytoma; Diffuse midline gliomas, H3 K27-altered; Diffuse hemispheric glioma, H3 G34-mutant; Diffuse pediatric-type HGG, H3-wildtype and IDH-wildtype.
    4. Malignant rhabdoid tumor (for Phase I) includes diagnoses of atypical teratoid/rhabdoid tumor (AT/RT), and rhabdoid tumor of the kidney (RTK), and other soft tissues as defined by 2 of the 3 following criteria; either (1)+(2) or (1)+(3): (1) Morphology and immunophenotypic panel consistent with rhabdoid tumor; (2) Loss of SMARCB1 confirmed by immunohistochemistry; (3) Molecular confirmation of tumor-specific bi-allelic SMARCB1 loss/mutation is encouraged in cases where SMARCB1 immunohistochemistry is equivocal, and required if SMARCB1 immunohistochemistry is not available
    5. Rhabdomyosarcoma (for Phase I) independent of fusion status and subtype
  4. Participants with CNS disease who are on should take stable doses for at least 7 days prior to first dose of ribociclib with no plans for escalation.
  5. Performance status:

    1. ≤ 16 years: Lansky Play score ≥ 50%
    2. >16 years: performance status ≥ 50% or \< 3
  6. of ≥ 12 weeks at the time of enrollment
  7. Adequate bone marrow function (bone marrow may be involved with tumor) and organ function
  8. Adequate hepatic, renal, cardiac function
  9. Females who are sexually active must agree to use highly effective during and for 6 months after treatment. Additionally, females of must have a negative serum pregnancy test within 7 days prior to the first dose of study medication. Pregnant or lactating females are not eligible for the study.
  10. Sexually active males (including those that have had a vasectomy), who do not agree to abstinence, must be willing to use a condom during intercourse while on study treatment and for 6 months after stopping treatment.

Exclusion criteria

Exclusion Criteria:

  1. Known to any of the of ribociclib or topotecan or temozolomide.
  2. Not recovered from clinical and laboratory acute toxicities related to prior anti-cancer therapies
  3. Concurrent severe and/or uncontrolled concurrent medical conditions (serious infections or significant cardiac, pulmonary, hepatic, psychiatric, GI disease, or other organ dysfunction) that in the investigator's judgement could compromise their ability to tolerate or absorb protocol therapy or would interfere with the study procedures or results
  4. , uncontrolled heart disease and/or cardiac repolarization abnormality
  5. History of prolongation; taking medications with a known risk to prolong the QT interval hat cannot be discontinued or replaced by safe alternative medication
  6. Currently taking medications that are mainly metabolized by /5 with a narrow therapeutic index, strong inducers or inhibitors of CYP3A4/5, herbal preparations/medications and dietary supplements
  7. Vaccinated with live, attenuated vaccines within 4 weeks
  8. Participated in a prior study within 30 days
  9. Received prior treatment with a CDK4/6 inhibitor
  10. Received last dose of anticancer therapy (including experimental) within 4 weeks
  11. Previous myeloablative therapy with autologous hematopoietic stem cell rescue within 8 weeks
  12. stem cell transplant within 3 months
  13. Has last fraction of radiation within 4 weeks
  14. Major surgery within 2 weeks
  15. Pregnant or nursing (breast feeding) female participant or female participant who plans to become pregnant or breast-feed during the trial.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Phase I-part A: Ribociclib + Topotecan and Temozolomide

    Participants with r/r NB, MB, HGG, MRT or RMS will be treated with ribociclib in combination with topotecan and temozolomide to determine MTD and/or RP2D. Ribociclib dose will be escalated with topotecan and temozolomide.

    Drug: Topotecan · Drug: Temozolomide · Drug: Ribociclib

Interventions

  • Starting out dose of topotecan administered at standard dose given to neuroblastoma patients (0.75 mg/m2/day).

    Also known as: Hycamtin

  • Starting out dose of temozolomide for cohort A1 and A2 for Phase 1-Part A: 150mg/m2/day. Starting out dose for subsequent cohorts, Cohort A3 and onwards, in Phase 1-Part A will initiate at 100mg/m2/day.

    Also known as: Temodar

  • Starting out dose of ribociclib for cohort A1 Phase 1-Part A: 200mg/m2/day. Starting out dose for Cohort A2 and A3 was 100mg/m2/day.

    Also known as: Kisqali, LEE011

06

What researchers measure

Primary outcomes

  1. Phase 1- Part A: Percentage of participants with Dose Limiting Toxicities (DLTs) in Cycle 1

    Percentage of participants with DLTs during first cycle of treatment (each cycle is 28 days) for each dose level associated with administration of ribociclib in combination with topotecan and temozolomide. A DLT is defined as an adverse event or abnormal laboratory value suspected to be related with study treatment.

    Time frame: Up to 28 days

Secondary outcomes

  1. Plasma concentrations of ribociclib (Phase I-Part A)

    Pharmacokinetic (PK) blood samples will be collected at selected time-points to determine ribociclib plasma concentrations from participants in Phase I-Part A, Phase I-Part B and Phase II

    Time frame: Cycle 1 day 1 and 15; Cycle 2 Day 15. Cycle=28 days

  2. Area under the plasma concentration-time curve (AUC) of ribociclib (Phase I-Part A)

    PK blood samples will be collected at selected time-points to determine AUC of ribociclib from participants in Phase I-Part A, Phase I-Part B and Phase II

    Time frame: Cycle 1 day 1 and 15; Cycle 2 Day 15. Cycle=28 days

  3. Maximum plasma concentration (Cmax) of ribociclib (Phase I-Part A)

    PK blood samples will be collected at selected time-points to determine Cmax of ribociclib from participants in Phase I-Part A, Phase I-Part B and Phase II

    Time frame: Cycle 1 day 1 and 15; Cycle 2 Day 15. Cycle=28 days

  4. Time of maximum plasma concentration (Tmax) of ribociclib (Phase I-Part A)

    PK blood samples will be collected at selected time-points to determine Cmax of ribociclib from participants in Phase I-Part A and Phase I-Part B.

    Time frame: Cycle 1 day 1 and 15; Cycle 2 Day 15. Cycle=28 days

  5. Percentage of participants with dose interruptions and dose reductions (Phase I-Part A)

    Percentage of participants with dose interruptions and dose reductions for participants in Phase I-Part A, Phase I-Part B and Phase II

    Time frame: Up to 12 months

07

Study locations

6 sites
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Cohen Children's Medical Center of New York
    New Hyde Park, New York 11040, United States
  • St Jude s Childrens Research Hospital
    Memphis, Tennessee 38105-2794, United States
  • Novartis Investigative Site
    Cologne, 50937, Germany
  • Novartis Investigative Site
    Milan, MI 20133, Italy
  • Novartis Investigative Site
    Sutton, Surrey SM2 5PT, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Feb 2025, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2022
First posted
Jun 23, 2022
StartActual
Dec 27, 2022
Primary completionActual
Feb 26, 2025
CompletionActual
Feb 26, 2025
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05429502
Collaborators
Innovative Therapies For Children with Cancer Consortium
Responsible party
Sponsor
First posted
Jun 23, 2022
Start date
Dec 27, 2022
Primary completion
Feb 26, 2025
Completion
Feb 26, 2025
Last update
Oct 10, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Topotecan · Temozolomide · Ribociclib

Start the discussion